{"id":148649,"date":"2026-10-23T04:51:29","date_gmt":"2026-10-23T04:51:29","guid":{"rendered":"https:\/\/www.europesays.com\/ch\/148649\/"},"modified":"2026-10-23T04:51:29","modified_gmt":"2026-10-23T04:51:29","slug":"st-pharm-which-received-equipment-and-technology-support-from-roche-sets-sights-on-major-rna-contract-manufacturing-orders-biggo-finance","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/ch\/148649\/","title":{"rendered":"ST Pharm, Which Received Equipment and Technology Support from Roche, Sets Sights on Major RNA Contract Manufacturing Orders \u2014 BigGo Finance"},"content":{"rendered":"<p>It has been belatedly confirmed that Swiss pharmaceutical company Roche provided some equipment free of charge and even transferred process technology to ST Pharm (237690), a South Korean contract development and manufacturing organization (CDMO) for ribonucleic acid (RNA) therapeutics, when the company was building its production base in 2018. Both companies say they cannot confirm the details, but industry observers see the nearly decade-long partnership potentially leading to large commercial-scale orders down the road.<\/p>\n<p>According to investment banking sources on the 22nd, when ST Pharm, a subsidiary of Dong-A Socio Holdings (000640), was building its first oligonucleotide plant in Banwol, Ansan, Gyeonggi Province, in 2018, Roche supported the facility with analytical method development, process development compliant with good manufacturing practice (GMP) standards, analytical method validation and microbial control technology. It was also at this time that Roche handed over some equipment free of charge. The specific details of the cooperation were not disclosed publicly at the time but were confirmed in the course of this reporting.<\/p>\n<p>Oligonucleotides are a key raw material for RNA therapeutics. Their synthesis pathways are complex and quality control is highly demanding, so process design and quality management systems are as decisive for a CDMO&#8217;s competitiveness as production equipment. Roche&#8217;s support focused on precisely this area. ST Pharm&#8217;s first plant is said to have also produced Phase 3 clinical trial samples for RNA therapeutics under development by Roche.<\/p>\n<p>Results followed. In 2019, ST Pharm became the first company in the oligonucleotide field to win Roche&#8217;s Bio CDMO Award and the first in the world to pass Roche&#8217;s process validation for oligonucleotide therapeutics. This validation is a procedure that confirms whether a drug production process can consistently produce products meeting quality standards. In 2022, ST Pharm became the first in Asia to pass a US Food and Drug Administration (FDA) pre-approval inspection (PAI) of an oligonucleotide production facility, earning external recognition for its quality capabilities.<\/p>\n<p>The history of cooperation between Roche and ST Pharm can be summarized in key milestones.<\/p>\n<p>TimingDetails2018Roche provides equipment free of charge to ST Pharm&#8217;s first oligonucleotide plant and supports process and analytical technology2019First in the oligonucleotide field to win Roche&#8217;s Bio CDMO Award; first in the world to pass Roche&#8217;s process validation2022First in Asia to pass FDA PAI for an oligonucleotide production facilitySeptember 2025Completion of the second oligonucleotide building at the Banwol campus in Ansan; annual capacity expanded from 6.4 moles to about 10 moles (up to 5 tons)<\/p>\n<p>Note: Capacity expansion targets 14 moles (about 7 tons) by 2029<\/p>\n<p>Roche once scaled back its RNA therapeutics research before resuming development with the 2014 acquisition of Denmark&#8217;s Santaris Pharma. Recently, it has been aggressively pursuing candidate compounds. In February, it licensed short interfering RNA (siRNA) candidates from China&#8217;s Sanejin Bio in a deal worth $1.7 billion (~2.3 trillion won), and this month it signed a contract with China&#8217;s Rona Therapeutics to license ALK7-targeting RNA interference (RNAi) candidates. The deal is worth up to $1.06 billion (~1.4 trillion won). ALK7 is a protein mainly expressed in fat cells that is involved in regulating fat metabolism.<\/p>\n<p>Its development areas are also broadening beyond rare diseases to obesity and metabolic diseases, central nervous system (CNS) disorders, cardiovascular diseases and infectious diseases. If candidates advance in diseases with large patient populations and long-term dosing needs, such as obesity or hypertension, demand will extend beyond clinical-grade raw materials to mass production after commercialization. Sepofarsen, an IgA nephropathy treatment Roche is co-developing with US-based Ionis, has reached Phase 3.<\/p>\n<p>ST Pharm has already built a track record as a CDMO for Big Pharma RNA therapeutics. According to Shinhan Securities, ST Pharm has won CDMO deals for five new drugs: Novartis&#8217;s hypercholesterolemia treatment Leqvio, Biogen&#8217;s spinal muscular atrophy treatment Spinraza, Ionis&#8217;s hypertriglyceridemia treatments Tryngolza and Dawnzera, and Geron Corporation&#8217;s Rytelo. Its collaboration with GSK is also drawing attention. GSK&#8217;s chronic hepatitis B treatment Hepcludex, for which ST Pharm is known to produce the active ingredient bepirovirsen, received FDA approval on the 20th (local time). As an antisense oligonucleotide (ASO)-based treatment now cleared for commercialization, additional volume expansion is expected.<\/p>\n<p>Capacity expansion is also accelerating. With the completion of the second oligonucleotide building in September last year, ST Pharm raised annual capacity from 6.4 moles to about 10 moles (up to 5 tons) and plans to expand it to 14 moles (about 7 tons) by 2029. &#8220;ST Pharm&#8217;s chances of producing new therapeutics have grown thanks to its long-standing cooperation with Roche and its experience winning Big Pharma orders,&#8221; a South Korean IB industry official said. &#8220;If it wins orders for large-scale RNA therapeutics such as obesity drugs, its growth potential will expand further.&#8221;<\/p>\n<p>The key question is how much volume ST Pharm will secure when Roche&#8217;s pipeline enters the commercialization stage. Roche&#8217;s precedent of directly supporting equipment and process technology shows the depth of the partnership, but some note it is too early for optimism, as commercial volume allocation is decided through separate competitive bidding and quality reviews. The fact that demand for raw materials could rise in steps if obesity and metabolic disease RNA therapeutics move to large-scale production is a factor in ST Pharm&#8217;s favor.<\/p>\n","protected":false},"excerpt":{"rendered":"It has been belatedly confirmed that Swiss pharmaceutical company Roche provided some equipment free of charge and even&hellip;\n","protected":false},"author":2,"featured_media":148650,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[124],"tags":[30284,51816,70658,41991,70659,206,70657,65282,134,70660,70656],"class_list":["post-148649","post","type-post","status-publish","format-standard","has-post-thumbnail","category-roche","tag-biogen","tag-cdmo","tag-dong-a-socio-holdings","tag-gsk","tag-hepcludex","tag-novartis","tag-oligonucleotide","tag-rna-therapeutics","tag-roche","tag-sepofarsen","tag-st-pharm"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@ch\/117488430907501086","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/148649","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/comments?post=148649"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/148649\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media\/148650"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media?parent=148649"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/categories?post=148649"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/tags?post=148649"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}